Loading...

Investor Alert: ADMA Biologics Securities Fraud Investigation After 29% Stock Decline

By |2026-04-10T08:57:50-04:00April 10th, 2026|Investor Alerts|

Overview: Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have incurred significant losses after a sharp stock decline linked to allegations of securities fraud related to revenue reporting. Background ADMA Biologics is currently under investigation by multiple law firms for potential violations of federal securities laws. (https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adma-biologics-inc---adma-302737867.html) The investigation focuses on whether the company and its [...]

Investor Alert: Kenneth Carl Ramos Customer Complaints and Termination Signal Potential Investor Risk

By |2026-04-10T08:45:39-04:00April 9th, 2026|Investor Alerts|

Investors who worked with Kenneth Carl Ramos should review their accounts in light of recent public disclosures regarding customer complaints and a prior employment separation. BrokerCheck reports multiple customer disputes and a termination-related event that may require further attention (BrokerCheck: Kenneth Carl Ramos — https://brokercheck.finra.org/individual/summary/2553426). Significance of These Disclosures Patterns of complaints and termination may [...]

Investor Alert: SEC Lawsuit Alleges $1.8M Fraud Scheme Involving Castle Hill Advisor

By |2026-04-09T11:29:50-04:00April 9th, 2026|Investor Alerts|

The U.S. Securities and Exchange Commission has filed an enforcement action alleging investor fraud involving John R. Brodacki III, a former advisor at Castle Hill Financial Group. This case highlights a recurring and concerning pattern in the securities industry:Trusted advisors allegedly divert client funds under the pretense of legitimate investment strategies, often targeting vulnerable investors. [...]

Investor Alert: Vincent Camarda Case Presents Significant Recovery Opportunities for Impacted Investors

By |2026-04-09T11:17:34-04:00April 9th, 2026|Investor Alerts|

Recent developments available through FINRA BrokerCheck involving Vincent Camarda (CRD# 1372052) have attracted heightened attention from regulators, arbitration panels, and investor advocates due to multiple customer complaints, regulatory actions, and substantial financial awards related to his conduct. Investors who have experienced losses may have a significant opportunity to seek recovery through FINRA arbitration and related [...]

Stirlingshire Investments FINRA Action: Leveraged ETF Violations and Investor Risk

By |2026-04-09T11:13:50-04:00April 9th, 2026|Broker / Advisor Investigations|

Recent disciplinary action by FINRA highlights compliance failures at Stirlingshire Investments involving recommendations of complex exchange-traded products to retail investors. According to FINRA, the firm failed to establish and enforce supervisory procedures related to the recommendation of inverse and leveraged ETFs, products that carry elevated risk and are generally intended for short-term trading strategies.Key Findings [...]

Independence Capital FINRA Action: Speculative Bond Sales to Retail and Senior Investors

By |2026-04-09T10:57:39-04:00April 9th, 2026|Broker / Advisor Investigations|

Recent FINRA action highlights serious concerns about Independence Capital Co., Inc. related to selling high-risk bonds to retail investors, including seniors. FINRA found the firm failed to reasonably supervise recommendations involving speculative, illiquid GWG L Bonds, suitable only for investors with substantial financial resources and no liquidity needs. Key Findings FINRA found that: Approximately $443,000 [...]

Aegis Capital Under FINRA Scrutiny: What Investors Should Know

By |2026-04-09T10:48:29-04:00April 9th, 2026|Broker / Advisor Investigations|

Aegis Capital Corp. is under renewed regulatory scrutiny after recent FINRA actions in early 2026. These actions underscore ongoing compliance issues related to private placements, securities distributions, and supervisory failures, all of which affect retail investors. This update centers on a recently accepted FINRA Letter of Acceptance, Waiver, and Consent (AWC). Regulation M Violations and [...]

FINRA March 2026 Disciplinary Actions Reveal Widespread Reg BI Failures, Private Placement Risks, and Supervisory Breakdowns

By |2026-04-08T14:08:54-04:00April 8th, 2026|Broker / Advisor Investigations, FINRA Enforcement Actions|

Introduction FINRA’s March 2026 disciplinary report highlights persistent failures in the brokerage industry that directly affect retail investors. The report identifies systemic issues, including unsuitable investment recommendations, private placement violations, supervisory breakdowns, and off-channel communications, which continue to expose investors to unnecessary risk. For investors, these findings signal potential harm and, in many cases, indicate [...]

Regulation D Explained: A Practical Guide to Private Offerings, Risks, and Investor Protection

By |2026-04-06T13:06:54-04:00April 6th, 2026|Securities Fraud & Investment Losses|

Regulation D is one of the most widely used yet misunderstood frameworks in modern investing. At its core, Regulation D allows companies to raise capital privately without registering securities for public sale. In practice, it creates an environment where opportunity and risk coexist, often divided by information that may not be immediately available to investors. [...]

The QC Capital Reg D Case: When Private Offerings Look Institutional but Transfer Risk to Investors

By |2026-04-06T11:17:56-04:00April 6th, 2026|Securities Fraud & Investment Losses|

A recent case analysis among fraud investigators has renewed attention to a fundamental risk in private offerings: deals that appear institutional can conceal materially different economics. The transaction centers on the Venice Park Apartments (formerly Advenir at Monterrey), a 243-unit multifamily property in Venice, Florida, syndicated through a Regulation D offering linked to groups including [...]

Go to Top